174 related articles for article (PubMed ID: 37410241)
21. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors.
Jardim DLF; Millis SZ; Ross JS; Lippman S; Ali SM; Kurzrock R
Oncologist; 2023 Feb; 28(2):e82-e91. PubMed ID: 36082904
[TBL] [Abstract][Full Text] [Related]
23. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Facchinetti F; Hollebecque A; Braye F; Vasseur D; Pradat Y; Bahleda R; Pobel C; Bigot L; Déas O; Florez Arango JD; Guaitoli G; Mizuta H; Combarel D; Tselikas L; Michiels S; Nikolaev SI; Scoazec JY; Ponce-Aix S; Besse B; Olaussen KA; Loriot Y; Friboulet L
Cancer Discov; 2023 Sep; 13(9):1998-2011. PubMed ID: 37377403
[TBL] [Abstract][Full Text] [Related]
24. Erdafitinib: First Global Approval.
Markham A
Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma.
Kardoust Parizi M; Margulis V; Lotan Y; Mori K; Shariat SF
Urol Oncol; 2021 Jul; 39(7):409-421. PubMed ID: 33642228
[TBL] [Abstract][Full Text] [Related]
26. Emerging Targeted Therapy for Bladder Cancer.
Thibault C; Loriot Y
Hematol Oncol Clin North Am; 2021 Jun; 35(3):585-596. PubMed ID: 33958152
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
[TBL] [Abstract][Full Text] [Related]
28. [Molecular tumor board-urothelial cancer].
Hupe MC; Gakis G; Seiler R
Urologe A; 2019 Jul; 58(7):760-767. PubMed ID: 31172245
[TBL] [Abstract][Full Text] [Related]
29. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
30. Erdafitinib for advanced urothelial carcinoma.
Burki TK
Lancet Oncol; 2019 Sep; 20(9):e469. PubMed ID: 31378458
[No Abstract] [Full Text] [Related]
31. [High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
Grülllich C
Urologe A; 2020 Apr; 59(4):478-479. PubMed ID: 32103289
[No Abstract] [Full Text] [Related]
32. RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma.
Clark-Garvey S; Kim WY
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779406
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
34. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Siefker-Radtke AO; Loriot Y
Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
[No Abstract] [Full Text] [Related]
35. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
[No Abstract] [Full Text] [Related]
36. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
37. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
38. Erdafitinib (Balversa) for urothelial carcinoma.
Med Lett Drugs Ther; 2024 May; 66(1702):e83-e84. PubMed ID: 38696316
[No Abstract] [Full Text] [Related]
39. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
Sethakorn N; O'Donnell PH
BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
[TBL] [Abstract][Full Text] [Related]
40. Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancer.
Osterman CK; Milowsky MI
Cancer; 2020 Jun; 126(11):2588-2591. PubMed ID: 32208525
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
